eClinical’s Industry Outlook 2024 report highlights a significant acceleration in AI/ML adoption for clinical trials. Over half of professionals (53%) in functions like clinical operations, data management, and biometrics now see these technologies as central to streamlining trials by 2024, surpassing the emphasis on automation that dominated last year. Despite this hype cycle, a core…
What biopharmas should know about RBM and RBQM
As a growing number of emerging biopharma companies seek to develop novel treatments for chronic diseases, the clinical trials market could be worth $78.3 billion by 2030. Clinical trials, however, continue to be difficult and expensive to manage. Yet successful clinical trials, however, remain critical for investors. Small biopharmas are thus looking for guidance in navigating…